Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peritrast is an ionic, iodinated X-ray contrast medium developed by Dr. Franz Köhler Chemie GmbH. It is unique among ionic contrast agents for its use of the amino acid lysine as a cation, rather than the standard sodium or meglumine, which was designed to improve the physiological tolerability of the medium. The drug's active components typically consist of amidotrizoic acid-lysine salt and sodium amidotrizoate. Peritrast is primarily indicated for diagnostic imaging of the urinary tract (urography) and is also utilized via oral or rectal administration for gastrointestinal imaging. Developed in the early 1960s, it remains a staple in the developer's portfolio of specialized niche pharmaceuticals for intensive care and diagnostic imaging.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Peritrast.